Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer

Overview of attention for article published in Breast Cancer Research, May 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#27 of 2,054)
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 19 news outlets
twitter: 6 X users

patent: 3 patents

Citations

dimensions_citation: 39 Dimensions

Readers on

mendeley: 39 Mendeley

Summary News X Patents Dimensions citations

So far, Altmetric has seen 3 patents that reference this research output.

LASOFOXIFENE COMBINATION TREATMENT OF ER+ BREAST CANCER THAT HAS PROGRESSED ON A CDK4/6…

Application WO-2023230222-A1

World Intellectual Property Organisation (WIPO)

METHODS OF TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES

Application WO-2023091550-A1

World Intellectual Property Organisation (WIPO)

LASOFOXIFENE TREATMENT OF AROMATASE-RESISTANT ER+ CANCER

Application WO-2023091553-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.